Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Production in Russia (August 2019)

Thursday, September 26, 2019

Between January and August 2019, Russia produced 255.8 bln RUB worth of pharmaceutical drugs (manufacturers’ prices, VAT included), which is in monetary terms (rubles) 20.2% higher than that of the same period in 2018. In physical terms, the dynamics are +4.5%, with the production volume of 2.83 bln units. If calculated in minimum dosage units (MDU), the dynamics are +3.5%, with the production volume of 47 bln MDUs.

The dynamics of the production in August 2019 are +22% in monetary terms and +11.6% in physical terms. The dynamics of the Rx drug production for the period between January and August 2019 are +13.8% in units and +12.5% in MDUs, while those of the OTC drug production are -1.4% in units and -5% in MDUs.

195 out of the 285 manufacturers of Rx drugs have positive dynamics for the period. Among the top 20 manufacturers with the highest production volume, only Stada has negative dynamics, with -13.6% in physical terms. The production of Enalapril, Mexiprim, Cardionate and others has dropped. The leader in the top 20 is Gedeon Richter, with the dynamics of +63% in physical terms. The production of the company’s Verospiron has risen by 4.6 times. While the production of most dosage forms is localized in full cycle, 25 mg tablets are imported in-bulk. Gedeon Richter is followed by Ozon, with +44% in physical terms. The production of its Meloxicam has risen by 20.8 times.

Among the 151 OTC drug manufacturers, 64 companies have negative dynamics. Moreover, 10 companies out of the top 20 has negative dynamics. Uralbiofarm has the lowest dynamics in the top 20, with -37% in physical terms. Acetylsalicylic Acid, Citramon, Activated Carbon, Allochol and Dibazol have the highest drop in production. Samaramedprom has the highest dynamics in the top 20, with the production of Pertussinum having risen by 7.6 times.

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2018 – August 2019)

Share: